Sign up to resume Huntington’s gene therapy trial |…
A data safety monitoring board has recommended that enrollment of the highest dosage group be resumed in the European Phase 1/2 trial of AMT-130 in people with Huntington’s disease, but with additional security measures in place. UniQure, the developer of the investigational treatment, announced in August that enrollment in this high-dose group was voluntarily halted …
Sign up to resume Huntington’s gene therapy trial |… Read More »
